Related Experiment Video
Updated: Aug 14, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
[The clinical spectrum of dermatomyositis]
Julia Kaufmann1, Nicolas Hunzelmann, Ekkehard Genth
1Klinik und Poliklinik für Dermatologie und Venerologie der Universität zu Köln. jost@netcologne.de
Abstract:
Dermatomyositis is characterized by marked clinical heterogeneity. Many classification schemes are available, based on internal organ involvement, presence of circulating autoantibodies and additional symptoms characteristic for other connective tissue diseases. Viral infections and underlying malignancies are possible mechanisms to trigger this autoimmune disease. Intensive clinical investigations to detect such malignancies are therefore required. The prognosis of the individual patient depends on the involvement of internal organs and the characterization of circulating autoantibodies. There are patients with rapidly developing subsets of dermatomyositis and those with slowly progressive disease. Therefore treatment has to be adjusted for the disease severity. Sometimes high dosages of corticosteroids in combination with immunosuppressive agents or immunoglobulins are required.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Inflammatory Bowel Disease IV: Clinical Manifestations
Myocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Toxidromes: Clinical Features